[Guidelines for type 1 Gaucher's disease]

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Gaucher's disease (GD) is a lysosomal storage disorder resulting from beta-glucosidase deficiency.
• This deficiency causes glycolipid accumulation in macrophages, affecting organs like the liver, spleen, and bone marrow.
• Neurological involvement is rare but possible.

Purpose of the Study:

• To summarize the key aspects of Gaucher's disease diagnosis and management.
• To highlight the importance of early detection and appropriate therapeutic strategies.

Main Methods:

• Diagnosis relies on measuring beta-glucosidase activity in leukocytes or fibroblasts.
• Genetic mutation analysis is crucial for confirmation.
• Biomarkers such as chitotriosidase activity and plasma CCL-18/PARC levels aid in assessment.

Main Results:

• GD presents with organomegaly, anemia, thrombocytopenia, or bone crises.
• Diagnostic confirmation requires specific enzyme and genetic testing.
• Treatment protocols involve enzyme replacement or substrate reduction therapy.

Conclusions:

• Accurate diagnosis of Gaucher's disease is essential for timely intervention.
• Monitoring treatment response is critical for achieving therapeutic goals.
• A multidisciplinary approach is recommended for managing this rare metabolic disorder.